Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which patients were dosed every 3 weeks. We hypothesized that dose intensification of ONC...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Wagner, Jessica, Kline, C. Leah, Zhou, Lanlan, Campbell, Kerry S., MacFarlane, Alexander W., Olszanski, Anthony J., Cai, Kathy Q., Hensley, Harvey H., Ross, Eric A., Ralff, Marie D., Zloza, Andrew, Chesson, Charles B., Newman, Jenna H., Kaufman, Howard, Bertino, Joseph, Stein, Mark, El-Deiry, Wafik S.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2018
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983321/
https://ncbi.nlm.nih.gov/pubmed/29533922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96711
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料